OptimizeRx (NASDAQ:OPRX) Price Target Cut to $13.00 by Analysts at B. Riley

OptimizeRx (NASDAQ:OPRX) had its price objective lowered by B. Riley from $17.00 to $13.00 in a research note released on Tuesday morning,Benzinga reports. B. Riley currently has a buy rating on the stock.

A number of other research analysts have also recently commented on the company. Stephens began coverage on OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target on the stock. Roth Mkm reiterated a “buy” rating and set a $16.00 target price (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Barclays decreased their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. JMP Securities cut their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th. Finally, Stifel Nicolaus reduced their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, OptimizeRx currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.19.

OptimizeRx Price Performance

Shares of OptimizeRx stock opened at $4.94 on Tuesday. The stock’s fifty day moving average is $5.31 and its 200 day moving average is $7.69. OptimizeRx has a one year low of $3.78 and a one year high of $16.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market cap of $91.00 million, a P/E ratio of -3.71 and a beta of 1.34.

Insider Buying and Selling

In other OptimizeRx news, CEO William J. Febbo bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the transaction, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OPRX. Barclays PLC boosted its holdings in OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after buying an additional 21,060 shares in the last quarter. Bullseye Asset Management LLC grew its position in shares of OptimizeRx by 55.6% during the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after acquiring an additional 76,458 shares during the period. BNP Paribas Financial Markets increased its stake in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares in the last quarter. Quest Partners LLC raised its holdings in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares during the period. Finally, Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 8.0% in the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after purchasing an additional 4,999 shares during the period. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.